Arthur Brothag is a Principal and joined Apax Partners in 2009. He is a member of the Healthcare team and is based in the London office. Arthur has participated in a number of key deals, including Vyaire Medical, Invent Farma/neuraxpharm, Acelity (formerly known as KCI), Unilabs and EVRY. He serves as a Board member of Vyaire Medical, Invent Farma/neuraxpharm and Unilabs, and as an Observer on the Acelity (KCI) board. Prior to joining Apax, Arthur worked in the healthcare teams at the private equity firm Warburg Pincus, as well as Morgan Stanley, both in London Arthur trained as a medical doctor with a state diploma and a doctorate from the Technical University of Munich; he held resident positions at University hospitals in Germany and Switzerland in internal medicine (cardiology and oncology). In addition to his medical and research training, he also completed his MBA studies with distinction at INSEAD Business School.